78 related articles for article (PubMed ID: 19331204)
1. Immunotherapy in patients with less than complete response to chemotherapy.
Recchia F; Candeloro G; Necozione S; Bisegna R; Bratta M; Rea S
Anticancer Res; 2009 Feb; 29(2):567-72. PubMed ID: 19331204
[TBL] [Abstract][Full Text] [Related]
2. Phase II randomized study of interleukin-2 with or without 13-cis retinoic acid as maintenance therapy in patients with advanced cancer responsive to chemotherapy.
Recchia F; Saggio G; Cesta A; Alesse E; Gallo R; Necozione S; Rea S
Anticancer Res; 2005; 25(4):3149-57. PubMed ID: 16080579
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced ovarian cancer.
Recchia F; Saggio G; Cesta A; Candeloro G; Nuzzo A; Lombardo M; Carta G; Rea S
Int J Oncol; 2005 Oct; 27(4):1039-46. PubMed ID: 16142321
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 and 13-cis retinoic acid in the treatment of minimal residual disease: a phase II study.
Recchia F; De Filippis S; Rosselli M; Saggio G; Fumagalli L; Rea S
Int J Oncol; 2002 Jun; 20(6):1275-82. PubMed ID: 12012010
[TBL] [Abstract][Full Text] [Related]
5. Phase 1B study of subcutaneously administered interleukin 2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer.
Recchia F; De Filippis S; Rosselli M; Saggio G; Cesta A; Fumagalli L; Rea S
Clin Cancer Res; 2001 May; 7(5):1251-7. PubMed ID: 11350891
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy.
Mantovani G; Macciò A; Madeddu C; Mulas C; Massa E; Astara G; Ferreli L; Mudu MC; Gramignano G; Murgia V; Lusso MR; Mocci M; Cardia A; Mura L
Oncol Rep; 2002; 9(4):887-96. PubMed ID: 12066227
[TBL] [Abstract][Full Text] [Related]
7. Low dose interleukin-2 and 13-cis-retinoic acid as maintenance therapy in patients with solid tumors responsive to chemotherapy.
Recchia F; Cesta A; Rea S
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):135-43. PubMed ID: 16767920
[TBL] [Abstract][Full Text] [Related]
8. Maintenance immunotherapy in metastatic breast cancer.
Recchia F; Sica G; Candeloro G; Necozione S; Bisegna R; Bratta M; Rea S
Oncol Rep; 2008 Nov; 20(5):1173-9. PubMed ID: 18949418
[TBL] [Abstract][Full Text] [Related]
9. Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II study.
Recchia F; Di Orio F; Candeloro G; Guerriero G; Piazze J; Rea S
Gynecol Oncol; 2010 Feb; 116(2):202-7. PubMed ID: 19880164
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
11. Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer.
Négrier S; Perol D; Ravaud A; Bay JO; Oudard S; Chabaud S; Fargeot P; Delva R; Deplanque G; Gravis G; Escudier B;
Clin Cancer Res; 2008 Sep; 14(18):5907-12. PubMed ID: 18794104
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of IL-2 immunotherapy in metastatic renal cell carcinoma in relation to the psychic profile as evaluated using the Rorschach test.
Messina G; Lissoni P; Bartolacelli E; Fumagalli L; Brivio F; Colombo E; Gardani GS
Anticancer Res; 2007; 27(4C):2985-8. PubMed ID: 17695482
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
[TBL] [Abstract][Full Text] [Related]
14. Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients.
Lissoni P; Brivio F; Fumagalli L; Messina G; Meregalli S; Porro G; Rovelli F; Vigorè L; Tisi E; D'Amico G
Anticancer Res; 2009 May; 29(5):1847-52. PubMed ID: 19443415
[TBL] [Abstract][Full Text] [Related]
15. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
16. Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer.
Recchia F; Saggio G; Nuzzo A; Biondi E; Di Blasio A; Cesta A; Candeloro G; Alesse E; Rea S
J Immunother; 2006; 29(1):87-94. PubMed ID: 16365604
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer.
Recchia F; Saggio G; Cesta A; Candeloro G; Di Blasio A; Amiconi G; Lombardo M; Nuzzo A; Lalli A; Alesse E; Necozione S; Rea S
Cancer Immunol Immunother; 2007 May; 56(5):699-708. PubMed ID: 16955297
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
Nakamura M; Wada J; Suzuki H; Tanaka M; Katano M; Morisaki T
Anticancer Res; 2009 Mar; 29(3):831-6. PubMed ID: 19414316
[TBL] [Abstract][Full Text] [Related]
19. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
[TBL] [Abstract][Full Text] [Related]
20. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.
Fontana A; Galli L; Fioravanti A; Orlandi P; Galli C; Landi L; Bursi S; Allegrini G; Fontana E; Di Marsico R; Antonuzzo A; D'Arcangelo M; Danesi R; Del Tacca M; Falcone A; Bocci G
Clin Cancer Res; 2009 Aug; 15(15):4954-62. PubMed ID: 19622584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]